General principles for preventing high INR Simple dental or dermatological procedures may not require interruption to warfarin therapy. Simple dental.

Slides:



Advertisements
Similar presentations
Presentation title Emergency Care Part 3: Surgery in Children with Diabetes.
Advertisements

Evidence-Based Management of Anticoagulant Therapy
What a Bloody Mess! A/Professor Kent Robinson Senior Staff Specialist, Liverpool & Campbelltown Hospitals.
Warfarin toxicity Presented by: Dr.Somaia Janah Presented by: Dr.Somaia Janah.
BLEEDING DISORDERS AN OVERVIEW WITH EMPHASIS ON EMERGENCIES.
Medications that impact bleeding By Nino Lalaiants Inesa Legrian NYCCT 2012.
NEW ORAL ANTICOAGULANTS
Transfusion Quiz “Their Lives in Your Hands” Doctors.
Octaplex – The Modern PCC
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Surgery with a Prosthetic Valve- What about the Warfarin? COPYRIGHT © 2014, ALL RIGHTS RESERVED From the Publishers of.
The EINSTEIN PE Study 'Xarelto' for the Acute and Continued Treatment of Symptomatic Pulmonary Embolism.
The EINSTEIN DVT Study 'Xarelto' for the Acute and Continued Treatment of Symptomatic Deep Vein Thrombosis.
Andres Ferber MD September
WARFARIN AN OVERVIEW.
Background Methods Results Conclusion Acknowledgements Printed by Multi-Institutional Audit of octaplex® & Comparison with National Recommendations S.
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Mark Bleackley MEDG 505 March.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
Anticoagulation Transitions: Perioperative Care Alan Brush, MD, FACP Clinical Co-Director, Anticoagulation Management Service Harvard Vanguard Medical.
INR for warfarin monitoring ©bpac nz, October 2006.
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
Emergency anticoagulant reversal B Vigué, DAR, CHU Bicêtre.
FERNE/EMRA How do we treat ICH patients with an elevated INR Andy Jagoda, MD, FACEP Professor and Vice Chair Department of Emergency Medicine Mount Sinai.
PRINCIPLES OF PROPHYLAXIS OF INFECTION 1)Procedure should have significant risk of infection 2)Choose correct antibiotic 3)Antibiotic plasma level must.
Factor II Deficiency By Jessica Johnson Medical Terminology II December 2, 2004.
Role of Factor Concentrates in Perioperative Coagulopathies Dr Neville Gibbs Department of Anaesthesia Sir Charles Gairdner Hospital.
 Background  Cost  Benefit  Complication.
DVT Prevention and Anticoagulant Management
Factor VII Deficiency Diagnosis and Management
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
Drugs Susan Louw Haematology Registrar. 4 Questions to ask: Can I stop? (What is the risk of thrombosis?) Should I stop? (What is the risk of bleeding?)
Anticoagulants and reversal
Agents Affecting Blood Clotting
Chapter 19 Agents affecting Blood Clotting. Blood Clotting p461 Clotting is necessary to prevent fatal loss of blood from a minor injury Thromboemboli.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Rare Bleeding Disorders Factor XI deficiency FX deficiency Fibrinogen deficiency Dr Niamh O’Connell The National Centre for Hereditary Coagulation Disorders,
Case 1 Shahinda wahba 5033 Dina bawahab 5090 Wid nahas 5069 Doaa bayumi 5580 Ayat al-hindy Latifa abdulrahman.
Warfarin Therapy Aaqid Akram MBChB (2013) Clinical Education Fellow.
Treatment of deep venous thrombosis and pulmonary embolism Anders Waage.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
April 23, 2015 Mini-Lecture Nathan King M.D. Anticoagulation Reversal Part 1: Warfarin.
Management Control or elimination of the underlying cause Severe DIC: – Control of hemodynamic parameters – Respiratory support – Surgery Attempts to treat.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
Systemic anticoagulation during ECMO is intended to control thrombin generation and limit the risk for thrombotic and hemorrhagic complications.
ANTICOAGULATION The objectives of this section are: To be able to write prescriptions according to local anticoagulation guidelines To know how to prescribe.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
Low Procedural Bleed Risk
Evidence-Based Management of Anticoagulant Therapy
Prothrombin complex concentrate
Presenter: Meng-Jiun Chiou Present data: 2017/7/10
Rapid Reversal of Warfarin Therapy in Patients with Intracranial / Intraspinal Bleeding Mount Auburn Hospital Blood Bank, Emergency Department, Critical.
A Challenging Case of Anticoagulant-Related GI Bleeding
Warfarin Toxicity Treatment & Management
Ortho Warfarin Dosing Protocol
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Anticoagulation Prepared by Cherie Gan.
Aug, 2016.
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Reversal Strategies for VKA: Truths and Misconceptions
Pharmacogenomics Genes and Drugs.
ARNO TRIAL (Antithrombotic Regimens aNd Outcome)
Anticoagulant Reversal
Periprocedural Management of Patients on Anticoagulation
Thrombophilia in pregnancy: Whom to screen, when to treat
Individualized heparin and protamine management in infants and children undergoing cardiac operations  Massimiliano Codispoti, MD, Christopher A Ludlam,
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
RE-ALIGN Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement.
Drug Summary Info Document Request / monitor Goal of therapy Action
Presentation transcript:

General principles for preventing high INR Simple dental or dermatological procedures may not require interruption to warfarin therapy. Simple dental or dermatological procedures may not require interruption to warfarin therapy. If necessary, warfarin therapy can be withheld 5 days before elective surgery, when the INR usually falls to below 1.5 and surgery can be conducted safely. If necessary, warfarin therapy can be withheld 5 days before elective surgery, when the INR usually falls to below 1.5 and surgery can be conducted safely. General principles for preventing high INR General principles for preventing high INR Avoid high loading doses of warfarin, Avoid high loading doses of warfarin, Potential warfarin–drug interactions need to be considered. Potential warfarin–drug interactions need to be considered. Aim for an INR level that balances the therapeutic goal with risk factors of bleeding on an individual basis. Aim for an INR level that balances the therapeutic goal with risk factors of bleeding on an individual basis. Avoid frequent dose adjustments. Avoid frequent dose adjustments. Avoid excessive increases in dose when INR drifts below target INR range. Avoid excessive increases in dose when INR drifts below target INR range.

Dramatic increase in number of patients receiving OAC Dramatic increase in number of patients receiving OAC Interindividual variation (environmental and genetic) Interindividual variation (environmental and genetic) Incidence of warfarin associated haemorrhage :fatal haemorrhage 1%/Y. Incidence of warfarin associated haemorrhage :fatal haemorrhage 1%/Y. Reversal :seriousness of bleeding,balance against thrombotic risk and speed and completeness of reversal Reversal :seriousness of bleeding,balance against thrombotic risk and speed and completeness of reversal Options include simple dose omission,vitamin K & factors replacement Options include simple dose omission,vitamin K & factors replacement FFP is less effective in correction of coagulopathy,volume overload & slow infusion rate than PCCs FFP is less effective in correction of coagulopathy,volume overload & slow infusion rate than PCCs PCCs are also subjected to virus inactivation PCCs are also subjected to virus inactivation

PCCs PCCs are intermediate purity pooled plasma products PCCs are intermediate purity pooled plasma products only HTDEFIX is licensed in UK for warfarin reversal only HTDEFIX is licensed in UK for warfarin reversal PCCs, (‘‘four factor concentrates’’), OR low VII (three) PCCs, (‘‘four factor concentrates’’), OR low VII (three) Amounts of protein C and S Amounts of protein C and S Optimum dose not established. Optimum dose not established. INR 2–3.9, 25 U/kg; INR 4–5.9, 35 U/kg; INR. 6, 50 U/kg. INR 2–3.9, 25 U/kg; INR 4–5.9, 35 U/kg; INR. 6, 50 U/kg. Thrombogenicity, exacerbation of DIC are dose related problems, Thrombogenicity, exacerbation of DIC are dose related problems, The current cost in the UK is around 25 pence/unit (total cost for a single treatment for a 70 kg individual £437 -£875. The current cost in the UK is around 25 pence/unit (total cost for a single treatment for a 70 kg individual £437 -£875. More expensive than the cost of FFP. ( unit of produced from UK plasma currently costs about £30). More expensive than the cost of FFP. ( unit of produced from UK plasma currently costs about £30). FFP that is methylene blue treated or produced from non-UK plasma is more expensive.) FFP that is methylene blue treated or produced from non-UK plasma is more expensive.)

On the basis of the current evidence, a PCC plus IV vitamin K is the treatment of choice for patients with major haemorrhage. On the basis of the current evidence, a PCC plus IV vitamin K is the treatment of choice for patients with major haemorrhage. A dose of 30 U/kg (regardless of INR) A dose of 30 U/kg (regardless of INR) Combination of PCC and FFP covers period before vitamin K1 has reached its full effect. Combination of PCC and FFP covers period before vitamin K1 has reached its full effect. Vitamin K1 is essential for sustaining the reversal achieved Vitamin K1 is essential for sustaining the reversal achieved Pre- and postoperative management of anticoagulation. bridging therapy. Pre- and postoperative management of anticoagulation. bridging therapy. Prolonged immobility,AF index event requiring anticoagulation occurred more than 3 months prosthetic valves VTE within the preceding 3 months Prolonged immobility,AF index event requiring anticoagulation occurred more than 3 months prosthetic valves VTE within the preceding 3 months Unfractionated heparin 24 hours preceding surgery Unfractionated heparin 24 hours preceding surgery